A fatal asthma attack looks like a crisis confined to the chest: airways narrow, their lining swells, and mucus crowds out what little space is left to breathe. A new analysis of tissue from people who died during an asthma attack suggests the immune events behind that collapse may not start in the lungs at all. Researchers who examined samples from hundreds of organ donors found disturbed immune activity not only in the airways but in lymph nodes tied to the gut, raising new questions about why a common respiratory condition turns deadly in a small number of cases.
What Happens Inside the Airways During an Attack
During a typical asthma attack, muscles contract around the airways while inflammation and mucus restrict airflow further, and that squeezing can damage the cells lining the airways themselves, potentially feeding still more inflammation. Most attacks resolve with treatment, but a small share end in death, and researchers have struggled to explain what separates a survivable attack from a fatal one. Studying immune activity across multiple organs at once is difficult in living patients, so immunologists Yoonseung Lee and Donna Farber of Columbia University and their colleagues turned to deceased organ donors instead. The team analyzed immune cells from the lungs, blood, spleen, jejunum, lung-associated and mesenteric lymph nodes, and bone marrow of 695 donors collected between 2012 and 2025. Of that group, 41 had died during an asthma attack, 78 had asthma but died from unrelated causes, and 576 had no documented history of the disease. The findings were published in Nature Communications and reported by ScienceAlert. Asthma is common enough that the stakes of the question are large: CDC surveillance data put the 2023 U.S. death toll at 3,624 people, most of them adults over 35.
An IgE Signature in Every Fatal Case
The first clear pattern involved immunoglobulin E, or IgE, an antibody that flags pollen, dust mites, or other harmless substances as threats and activates mast cells to trigger inflammation and mucus production. Every donor in the fatal-asthma group whose IgE was measured had levels above the standard reference threshold. Their lungs also carried larger populations of type 2 helper T cells, type 2 innate lymphoid cells, and mast cells, the cell types most associated with allergic-style, “type 2” inflammation. When these cells become overactive, they can amplify swelling and mucus buildup in airways that are already narrowing.
Lymph Nodes as the Unexpected Hot Spot
To trace where that inflammatory signal was being organized, the researchers turned to lymph nodes, the sites where immune cells exchange information and coordinate a response before symptoms ever appear. “What surprised us most was where some of the strongest immune abnormalities appeared,” Lee told ScienceAlert. “We expected the lung to carry much of the signal, but we also found striking differences in the lymph nodes associated with the lungs and the gut – sites where immune responses are organized rather than where asthma symptoms are directly experienced.” Memory T and B cells, which record past immune encounters so the body can respond faster the next time, accumulated in mucosal-associated lymph nodes of fatal-asthma donors at younger ages than in donors without asthma, a pattern more typically associated with aging immune systems.
Weaker Brakes on the Immune Response
The lung-associated lymph nodes in fatal-asthma donors also contained markedly fewer regulatory T cells, the specialized cells that normally rein in an overactive immune response. That shortfall showed up both in donors who died during an attack and in those who had asthma but died of unrelated causes, suggesting the deficit tracks with the disease itself rather than only the final, fatal exacerbation. Combined with the surplus of type 2 inflammatory cells, the pattern suggested an immune system with a stronger accelerator and a weaker set of brakes.
Why the Gut Connection Doesn’t Mean What It Sounds Like
The most striking finding emerged when the team compared activity across tissues: in the fatal-asthma group, immune populations in the lungs showed far more association with responses happening in gut-associated lymph nodes than they did in donors without asthma. That doesn’t mean a meal, a digestive problem, or gut bacteria triggers a fatal attack. The donors’ intestinal lining itself wasn’t the focus; the signal involved immune cells sitting in lymph nodes near the intestines, tissue that organizes immune responses rather than tissue where food is digested. Earlier research has linked certain early-life gut bacteria to later asthma risk, but this study did not examine diet, digestion, or microbial composition at all.
Associations, Not Yet a Test or a Treatment
Lee was direct about the limits of the work: “Importantly, our study shows associations rather than causation.” Each donor supplied only a single snapshot of their immune system, so the researchers could not track whether immune cells moved between the gut and the lungs over time, or determine whether the abnormalities caused the fatal attacks or resulted from them. The fatal-asthma group was also relatively small, and information on prior corticosteroid use, which can alter immune cell counts, was not available for comparison. The authors say further transcriptomic and spatial analyses may eventually identify the specific molecular pathways involved, but for now the study offers neither a diagnostic test nor a new therapy — only a map of where, beyond the lungs, the immune system may be setting the stage for a fatal attack.
This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.
More from Morning Overview
